Chimerix (CMRX) Stock Price
Chimerix Price
Revenue at Chimerix has contracted by 13.9% per year over the past 14 years to 212,000.00 USD. For Chimerix, the net margin of -41,692.0% is down versus -784.2% a few years ago. The consensus 12-month price target for Chimerix is 8.72 USD, about 2.1% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
Chimerix stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Chimerix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Chimerix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Chimerix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Chimerix Price |
|---|
Chimerix Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Chimerix Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.00 | 10.00 | 5.00 | 4.00 | 7.00 | 12.00 | 5.00 | 1.00 | 33.00 | – | – | 6.00 | 38.00 | 189.00 | 318.00 | 791.00 |
| – | 150.00 | -50.00 | -20.00 | 75.00 | 71.43 | -58.33 | -80.00 | 3,200.00 | – | – | – | 533.33 | 397.37 | 68.25 | 148.74 |
| -1,025.00 | 100.00 | 100.00 | -1,100.00 | -685.71 | -208.33 | 100.00 | 100.00 | 100.00 | – | – | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| -41.00 | 10.00 | 5.00 | -44.00 | -48.00 | -25.00 | 5.00 | 1.00 | 33.00 | 33.00 | 33.00 | 6.00 | 38.00 | 189.00 | 318.00 | 791.00 |
| -58.00 | -118.00 | -77.00 | -72.00 | -71.00 | 13.00 | -44.00 | -173.00 | -60.00 | -93.00 | -96.00 | -5.00 | -65.00 | -189.00 | -318.00 | -791.00 |
| -1,450.00 | -1,180.00 | -1,540.00 | -1,800.00 | -1,014.29 | 108.33 | -880.00 | -17,300.00 | -181.82 | – | – | -83.33 | -171.05 | -100.00 | -100.00 | -100.00 |
| -59.00 | -117.00 | -76.00 | -70.00 | -69.00 | -173.00 | -42.00 | -255.00 | 172.00 | -82.00 | -88.00 | -108.00 | -73.00 | 25.00 | 123.00 | 358.00 |
| 63.89 | 98.31 | -35.04 | -7.89 | -1.43 | 150.72 | -75.72 | 507.14 | -167.45 | -147.67 | 7.32 | 22.73 | -32.41 | -134.25 | 392.00 | 191.06 |
| 39.13 | 46.15 | 46.43 | 47.34 | 50.72 | 61.39 | 62.70 | 86.87 | 88.05 | 88.91 | 90.26 | 90.26 | 90.26 | 90.26 | 90.26 | 90.26 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Chimerix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Chimerix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Chimerix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Chimerix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Chimerix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Chimerix stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Chimerix Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Chimerix business model & stock analysis
Chimerix SWOT Analysis
Strengths
Chimerix Inc has a diverse and innovative product portfolio that includes several successful drugs and therapies.
The company is led by a highly skilled and knowledgeable management team with extensive experience in the pharmaceutical industry.
Weaknesses
Chimerix Inc heavily relies on a small number of products for its revenue, which exposes it to risks in case of any failures or market decline.
The company's operations are primarily concentrated in specific geographic regions, limiting its potential market reach and growth opportunities.
Opportunities
With the increasing prevalence of various diseases and disorders, there is a growing demand for new and effective therapies, creating an opportunity for Chimerix Inc to expand its product offerings.
Forming strategic collaborations and partnerships with other pharmaceutical companies or research organizations can help Chimerix Inc access new markets, technologies, and resources.
Threats
The pharmaceutical industry is highly competitive, with numerous established players and new entrants. Chimerix Inc faces the risk of losing market share to competitors offering similar products.
The company operates in a heavily regulated industry, and changes in government regulations or non-compliance issues can significantly impact Chimerix Inc's operations and profitability.
Chimerix Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Chimerix Segments
Chimerix Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Chimerix Revenue by Segment (2/2)
3 Years
Max
Details
Chimerix Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Chimerix historical P/E ratio, EBIT multiple, and P/S ratio
Chimerix annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Chimerix shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Chimerix forecasts and price targets in August 2026
Analyst Price Targets 2026Chimerix Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 3/6/2025 | Downgrade | BuyHold | – | |
| 3/5/2025 | Downgrade | BuyHold | 57 | |
| 3/5/2025 | Downgrade | BuyNeutral | – | |
| 2/18/2025 | Maintained | Buy | – | |
| 12/30/2024 | Maintained | Buy | – | |
| 12/11/2024 | Maintained | Buy | – | |
| 11/18/2024 | Maintained | Outperform | 55 | |
| 11/11/2024 | Maintained | Buy | – | |
| 8/14/2024 | Maintained | Buy | – | |
| 3/1/2024 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Chimerix Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/11/2025 | -0.29USD | - | 0.00USD | - | 2025 Q2 |
| 5/2/2024 | -0.22USD | - | 153,000.00USD | - | 2024 Q1 |
| 2/29/2024 | -0.24USD | - | 59,741.00USD | - | 2023 Q4 |
| 8/7/2023 | -0.26USD | - | 152,249.00USD | - | 2023 Q2 |
| 5/15/2023 | -0.26USD | - | 152,249.00USD | - | 2023 Q1 |
| 2/27/2023 | -0.24USD | - | 490,752.00USD | - | 2022 Q4 |
| 11/3/2022 | 2.18USD | - | 222.66 MUSD | - | 2022 Q3 |
| 8/8/2022 | -0.25USD | - | 20,502.00USD | - | 2022 Q2 |
| 5/16/2022 | -0.34USD | - | 405.00USD | - | 2022 Q1 |
| 3/1/2022 | -0.18USD | - | 17.81 MUSD | - | 2021 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Chimerix stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Chimerix shareholder structure
| % | Name |
|---|---|
3.68783% | |
0.42718% | |
0.16655% | |
0.16487% | |
0.16000% | |
0.13760% |
Chimerix Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
16.37% | SEC ↗ | |
14.80% | SEC ↗ | |
14.80% | SEC ↗ | |
14.80% | SEC ↗ | |
11.00% | SEC ↗ | |
10.50% | SEC ↗ | |
10.50% | SEC ↗ | |
10.50% | SEC ↗ | |
10.50% | SEC ↗ | |
10.50% | SEC ↗ |
Chimerix Executives and Management Board
2 members · 50 % women
Mr. Alan Campion
Chief Financial Officer, Director · since 2025
Ms. Andrea Burke
Vice President
Chimerix Supply Chain
Chimerix Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.66 | 0.74 | 0.54 | ||
| 2 | -0.62 | 0.28 | 0.34 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Shenzhen Hepalink Pharmaceutical Group H | 0.65 | 0.83 | — | |
| 2 | -0.60 | -0.70 | -0.40 |
Frequently asked questions about Chimerix
Chimerix Inc. operates with a business model focused on the development and commercialization of innovative antiviral therapeutics. The company aims to address unmet medical needs and improve patients' lives through the discovery, research, and development of novel antiviral medications. Chimerix Inc. primarily focuses on developing oral nucleotide analogs that target viral replication and replication pathways, aiming to provide effective treatments for various viral infections. With its commitment to advancing medical science, Chimerix Inc. leverages its expertise to create valuable pharmaceutical solutions, contributing to the advancement of antiviral therapeutics.
Chimerix Inc primarily operates in the biotechnology and pharmaceutical industries.
The main competitors of Chimerix Inc in the market include pharmaceutical companies such as Gilead Sciences, Merck & Co., and GlaxoSmithKline.
Chimerix Inc is a pharmaceutical company based in Durham, North Carolina. Founded in 2002, the company primarily focuses on the development and commercialization of innovative antiviral therapeutics. Chimerix has a rich history in the field of antiviral research and has made significant contributions to the medical community. The company's mission is to discover, develop, and deliver novel medicines to improve the lives of patients suffering from life-threatening diseases. With a dedicated team of scientists and researchers, Chimerix continues to advance its pipeline of antiviral drugs, providing hope for patients worldwide.
Chimerix Inc has achieved significant milestones throughout its history. One notable achievement was the successful completion of Phase 3 clinical trials for its antiviral drug, brincidofovir. This marked a crucial milestone in the company's efforts to develop an effective treatment for viral infections, including cytomegalovirus. Additionally, Chimerix Inc has secured multiple partnerships and collaborations with renowned healthcare organizations and research institutions. These partnerships have paved the way for further advancements in Chimerix's drug development pipeline and enhanced its potential to address unmet medical needs. Chimerix Inc continues to strive for further milestones and innovations in the field of antiviral therapeutics.
Chimerix Inc is primarily present in the United States.
Chimerix Inc is a biopharmaceutical company that is committed to improving the lives of patients suffering from life-threatening diseases. Their corporate philosophy revolves around innovation, collaboration, and patient-centered care. Chimerix Inc values scientific excellence, integrity, and transparency in all aspects of their operations. They strive to develop novel antiviral therapies to address unmet medical needs. With a dedicated team of experts, Chimerix Inc focuses on delivering innovative solutions that can make a significant impact in the medical field. This commitment to patients, scientific advancement, and ethical practices defines Chimerix Inc and sets them apart in the biopharmaceutical industry.
Analysts currently set an average price target of 8.71 USD for the Chimerix stock (median: 8.72 USD), implying +2.0 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Chimerix stock: 7 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Chimerix to generate revenue of 38.60 M USD and earnings per share of -0.81 USD.
Converted at the current exchange rate, the Chimerix share trades at 7.32 EUR (8.54 USD).
The Chimerix share (CMRX) is listed on 5 stock exchanges, including: NASDAQ (CMRX), Frankfurt (CXF.F), München (CXF.MU), Düsseldorf (CXF.DU), SIX (Zürich) (CXF.SW).
Chimerix Inc is a US biotech company specializing in the development of antiviral and immunoncology therapeutics. It was founded in 2000 and is headquartered in Durham, North Carolina. The company's business model focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases and cancer. Chimerix operates in two main areas: infectious diseases and cancer. In infectious diseases, its leading product is Brincidofovir (BCV) for the treatment of life-threatening virus infections such as cytomegalovirus (CMV) and adenovirus infections. In cancer therapy, Chimerix has multiple products in its pipeline that aim to activate the immune system to fight tumors. The company collaborates with leading academic and clinical research institutions and utilizes various business models to market its products, including partnerships with government-funded research programs and multinational pharmaceutical companies. Overall, Chimerix has a promising pipeline of products in clinical studies and is well-positioned to improve global patient care.
The expected revenue of Chimerix is 38.60 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Chimerix is -73.55 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Chimerix is currently -10.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Chimerix stock.
The price-to-sales ratio (P/S) of Chimerix is currently 19.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Chimerix stock.
The Eulerpool Quality Score for Chimerix is 1/10.
The ISIN of Chimerix is US16934W1062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Chimerix is A1T65B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Chimerix is CMRX. The ticker symbol is used to trade Chimerix shares on the stock exchange.
Chimerix paid dividends every year for the past 0 years.
Chimerix is assigned to the 'Health' sector.
The dividends of Chimerix are distributed in USD.
Chimerix stock
Chimerix Peer Group
Chimerix Ticker
Chimerix FIGI
All fundamentals and in-depth analysis of Chimerix
Our stock analysis for Chimerix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chimerix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.